OvagenvsLivagen

Molecular Formula

C₁₅H₂₅N₃O₈

Molecular Weight

375.4 g/mol

Half-Life

Short plasma half-life typical of tripeptides; biological effects persist for weeks through epigenetic modifications to hepatic gene expression; metabolized to constituent amino acids (glutamic acid, aspartic acid, leucine)

Bioavailability

Effective via oral capsule (10 mg twice daily), sublingual liquid (0.1 mg/mL), and subcutaneous injection routes; penetrates cell membranes and nuclear membranes as a cell-penetrating peptide; tissue-specific activity demonstrated in organotypic hepatic cultures at 10⁻⁶ to 10⁻⁹ M

CAS Number

Not assigned (proprietary Khavinson peptide)

Molecular Formula

C₁₈H₃₁N₅O₉

Molecular Weight

461.5 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)

Bioavailability

Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli

CAS Number

Not assigned (research compound)

Common

• Mild digestive discomfort
• Mild fatigue
• Mild headache
• Minor appetite changes

Uncommon

• Mild nausea

Serious

• No documented serious adverse effects

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Digestive enzyme changes

Uncommon

• Transient flu-like symptoms

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Ovagen demonstrates favorable safety in reproductive endocrinology applications with no serious adverse events reported in clinical ovulation induction studies. As a kisspeptin analog, primary safety consideration is ovarian hyperstimulation syndrome (OHSS) risk, requiring careful hormone monitoring and patient education on abdominal pain, bloating, and nausea symptoms. Mild headaches and injection site reactions occur in <10% of users. Reproductive safety in animal models shows normal fetal development with no teratogenicity.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, leucine)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xSevere glutamic acid metabolism disorders (extremely rare)
• xActive autoimmune hepatitis in flare without physician supervision

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive autoimmune conditions in flare without physician supervision
• xConcurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism